Endurant Capital Management LP Biomarin Pharmaceutical Inc Transaction History

Endurant Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $2.97 Million - $3.84 Million	-38,952 Reduced 89.34%	4,650 $448,000
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $18.4 Million - $21.3 Million	-212,014 Reduced 82.94%	43,602 $3.78 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $15 Million - $20.1 Million	171,259 Added 203.02%	255,616 $24.9 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $4.94 Million - $6.63 Million	-61,017 Reduced 41.97%	84,357 $8.73 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $9.81 Million - $11.6 Million	119,399 Added 459.67%	145,374 $12.3 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $1.86 Million - $2.26 Million	25,975 New	25,975 $2.15 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $2.28 Million - $3.55 Million	-28,599 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $2.04 Million - $2.77 Million	28,599 New	28,599 $2.42 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $784,467 - $935,563	-10,100 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $815,676 - $960,813	10,100	10,100 $901,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.